Skip to main content

Table 2 Annual costs in Euros for non-metastatic and metastatic to bone prostate cancer patients with biochemical recurrence

From: Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France

Cost itemPatients without bone metastases (n = 48)Patients with bone metastases (n = 7)
Androgen deprivation therapy523 (364–695)691 (244–1165)
Hospitalisation costs
 First year (with salvage radiation therapy)2601 (1376–4381)3706 (491–8138)
 Other years921 (431–1510)3706 (631–7973)
Total costs
 First year3524 (2277–5246)4816 (1615–9234)
 Subsequent years1844 (1354–2434)4815 (1689–9308)
  1. Mean annual treatment/management costs with 95% confidence interval. Total costs included hospitalization costs, monitoring costs (office visit, biology and imaging) and drugs costs